{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-102570","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2026-08-28T10:00:29+00:00","discovered_at":"2026-08-28T10:10:00.268791+00:00","generated_at":"2026-08-28T10:10:07.024444+00:00","sec_items":["1.01","1.03"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"BioXcel files Chapter 11, sells assets to Teva for $57.5M upfront plus milestones","bullets":["Filed Chapter 11 petitions on Aug 27, 2026 in Delaware; operates as debtor-in-possession.","DIP financing from Oaktree and QIA: up to $19M new money plus $58.25M roll-up.","Stalking Horse APA with Teva: $57.5M upfront, up to $67.5M development milestones, up to $20M commercial milestones.","Appointed Samir Saleem as Chief Restructuring Officer, reporting to Board's Strategic Process Committee.","Sale subject to higher bids and court approval; transaction target close by Oct 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-102570","json":"https://secwatch.observer/filing/0001104659-26-102570.json","markdown":"https://secwatch.observer/filing/0001104659-26-102570.md","text":"https://secwatch.observer/filing/0001104659-26-102570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926102570/0001104659-26-102570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926102570/tm2624233d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-28T10:10:07.024444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}